VolitionRx says test can slash colorectal cancer 'false positives'

In combination with a traditonal screen the study saw almost a 97% detection rate for colorectal cancer

picture of blood phials
Accurate and a lot less uncomfortable

Use of its NuQ blood tests alongside traditional colorectal cancer screens can reduce the number of colonoscopies by a quarter, according to VolitionRx Limited (NYSE MKT:VNRX).

Presenting to the European Society for Medical Oncology Congress (ESMO), Volition Rx said a combination of an NuQ to test for colorectal cancer (CRC) combined with the conventional faecal immunochemical screening test registered almost a 97% detection for colorectal cancer.

Marielle Herzog, Volition’s lead nucleosomic scientist, said: "False positives add to an already long waiting list and delays diagnosis for patients who have cancer and need swift treatment.

“By undertaking this simple, cost effective blood test in people with a positive faecal test, we can help prevent unneeded referrals for colonoscopy with a small reduction in cancer detection and potentially reduce the colonoscopy waiting time for those at high risk of cancer."

Using NuQ with a faecal test can also increase screening subject throughput by a third.

Volition plans initially to focus the launch in large European Union countries.

It expects to receive CE Marking for this test later this year and to market the CRC test throughout Europe in 2017.

Quick facts: VolitionRx

Price: 4.48 USD

Market Cap: $184.09 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...



VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

1 week, 4 days ago

2 min read